JP2010514683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514683A5 JP2010514683A5 JP2009543166A JP2009543166A JP2010514683A5 JP 2010514683 A5 JP2010514683 A5 JP 2010514683A5 JP 2009543166 A JP2009543166 A JP 2009543166A JP 2009543166 A JP2009543166 A JP 2009543166A JP 2010514683 A5 JP2010514683 A5 JP 2010514683A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heterocycloalkyl
- heteroaryl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims 19
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 19
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 16
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 claims 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102100037346 Substance-P receptor Human genes 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- -1 antipsychotic Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000000841 delta opiate receptor agonist Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87097906P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/088053 WO2008079847A1 (en) | 2006-12-20 | 2007-12-19 | Compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514683A JP2010514683A (ja) | 2010-05-06 |
| JP2010514683A5 true JP2010514683A5 (enExample) | 2010-12-16 |
Family
ID=39562912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543166A Pending JP2010514683A (ja) | 2006-12-20 | 2007-12-19 | 化合物及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100016284A1 (enExample) |
| EP (1) | EP2099459A4 (enExample) |
| JP (1) | JP2010514683A (enExample) |
| CN (1) | CN101622002A (enExample) |
| WO (1) | WO2008079847A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2307389T3 (pl) | 2008-06-20 | 2013-05-31 | Astrazeneca Ab | Pochodne dibenzotiazepiny i ich zastosowanie |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| USD1032722S1 (en) | 2022-04-19 | 2024-06-25 | Ags Llc | Gaming machine |
| USD1032723S1 (en) | 2022-04-19 | 2024-06-25 | Ags Llc | Gaming machine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| US5538965A (en) * | 1993-12-23 | 1996-07-23 | Allelix Biopharmaceuticals Inc. | Dopamine receptor ligands |
| US6890919B2 (en) * | 2001-06-26 | 2005-05-10 | Shitij Kapur | Atypical antipsychotic agents having low affinity for the D2 receptor |
| US7208497B2 (en) * | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
| US20060217366A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating schizophrenia and other disorders |
| PL1696931T3 (pl) * | 2003-12-22 | 2009-10-30 | Acadia Pharm Inc | Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych |
-
2007
- 2007-12-19 EP EP07865845A patent/EP2099459A4/en not_active Withdrawn
- 2007-12-19 WO PCT/US2007/088053 patent/WO2008079847A1/en not_active Ceased
- 2007-12-19 JP JP2009543166A patent/JP2010514683A/ja active Pending
- 2007-12-19 CN CN200780051504A patent/CN101622002A/zh active Pending
- 2007-12-19 US US12/520,162 patent/US20100016284A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540637A5 (enExample) | ||
| CN115154470B (zh) | 使用食欲素-2受体拮抗剂治疗抑郁症的方法 | |
| TWI224102B (en) | Serotonergic agents | |
| JP2011006431A (ja) | アデノシンＡ２ａレセプターアンタゴニストの使用 | |
| TWI568733B (zh) | 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物 | |
| RU2012141706A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств в отношении метаботропных глутаматных рецепторов-842 | |
| JP2016527263A (ja) | ブロモドメイン阻害剤としての新規キナゾリノン | |
| KR20140107574A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| TW201920166A (zh) | 二氫吡咯並吡啶衍生物 | |
| JP2010531292A5 (ja) | １１−ピペラジン−１−イルジベンゾ[ｂ,ｆ][１,４]チアゼピンの誘導体及びその使用 | |
| WO2009017453A1 (en) | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 | |
| TW201831460A (zh) | 雜芳基苯氧基苯甲醯胺kappa類鴉片配體 | |
| JP2010514682A5 (enExample) | ||
| JP2006522128A5 (enExample) | ||
| CA2555172A1 (en) | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders | |
| JP2010514683A5 (enExample) | ||
| JP2019537581A5 (enExample) | ||
| KR20020090153A (ko) | 알콜중독 또는 알콜 의존을 위한 배합 치료 | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| KR20180101568A (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
| WO2024130065A1 (en) | Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions | |
| JP2010513489A5 (enExample) | ||
| JP2016523939A (ja) | 代謝型グルタミン酸受容体アンタゴニストとしてのエチニル誘導体 | |
| JPWO2017119456A1 (ja) | せん妄の予防または治療剤 | |
| JP2010514684A5 (enExample) |